From new treatment options for dry eye disease to type 2 diabetes, here are a few of the top U.S. Food and Drug Administration drug decisions expected this year
In the U.S. Food and Drug Administration (FDA)’s latest annual report of drug approvals, the agency shared it approved a total of 46 novel drugs in 2025. Here’s how that stacks up against years prior, and what that might mean for the year ahead.
Abby Kim, PharmD, BCOP, is a senior director, clinical strategy and oncology specialty solutions, shares key takeaways from the American Journal of Managed Care (AJMC) forum, “Bridging evidence and access in advanced small cell lung cancer.”
Understanding the patient journey and leveraging trend insights to manage high-cost specialty drugs on the medical benefit
Maryam Tabatabai, PharmD, associate vice president of clinical information, offers predictions about forthcoming drug approvals, the latest on a new voucher pilot, updated biosimilar guidance and more
A strategic deep dive into the latest trend report from Prime Therapeutics reveals how oncology spend is evolving across benefits and what it means for cancer care management
Nationwide effort on Oct. 25 offers opportunity to safely dispose of unused or expired medications
From benchmarking to biosimilars, this annual report has evolved into a strategic compass for navigating medical and specialty drug spend
New continuing education course showcases her expertise in biomarker testing and targeted therapy for EGFR-mutated NSCLC
Enhanced strategic consultation and new products like Medicare Predictive Model and Enrollment Capabilities are changing Prime’s government programs and delivering better access and costs to members
Login Portals
Compliance / Legal
Company
